Vertex at ASN Kidney Week 2026: renal push gathers pace
Covered in this story
Analyst targets on Vertex Pharmaceuticals
- UBS: $528 → $615 by Sep 2027 · Buy via Investing.com
- H.C. Wainwright: $515 → $641 by Sep 2027 · Buy via Investing.com
- BMO Capital Markets: $515 → $600 by Sep 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $VRTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Vertex Pharmaceuticals →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.